31-45 of 344
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Case: Implementing ADT Intensification in mHSPC
MinuteCE®Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
- advertisement
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
- MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
First 5 Minutes®: Empowering Shared Decisions in Lung Cancer Screening
CME/CEFirst 5 Minutes®: Empowering Shared Decisions in Lung Cancer Screening
Brett Bade, MD
Michael Gieske, MD
Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
CME/CEChairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
Jean Hoffman-Censits, MD
Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
CME/CEChairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
Kathleen N. Moore, MD, MS
- advertisement
Jennifer Johnson, MD, PhD
Adam J. Luginbuhl, MD
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
MinuteCE®Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Adam J. Luginbuhl, MD
